Harvard Pilgrim Health Care — a Point32Health company operating commercial plans in Massachusetts, Maine, New Hampshire, and Rhode Island — administers pharmacy benefits through Optum Rx. In 2026, Harvard Pilgrim dramatically reshaped its GLP-1 receptor agonist coverage: most formularies now exclude GLP-1 medications prescribed for weight loss and related conditions such as cardiovascular disease, while continuing to cover incretin therapies for type 2 diabetes with prior authorization and new clinical criteria.
This guide maps which GLP-1 medications Harvard Pilgrim covers under which diagnoses, details the January and May 2026 policy changes, explains formulary-level variation, and provides step-by-step guidance for prior authorization and exceptions. It is independent information and not medical advice or reimbursement guidance for a specific patient or plan.
Quick answer
| GLP-1 Drug | Harvard Pilgrim T2D Coverage | Harvard Pilgrim Weight-Loss Coverage (2026) |
|---|---|---|
| Ozempic (semaglutide injection) | Covered with PA (T2D diagnosis + oral hypoglycemic trial) | Excluded on Core, Select, ConnectorCare formularies |
| Mounjaro (tirzepatide injection) | Covered with PA (T2D diagnosis + oral hypoglycemic trial) | Excluded on Core, Select, ConnectorCare formularies |
| Rybelsus (semaglutide tablets) | Covered with PA (T2D diagnosis + oral hypoglycemic trial) | Excluded on Core, Select, ConnectorCare formularies |
| Trulicity (dulaglutide) | Covered with PA (T2D diagnosis + oral hypoglycemic trial) | Excluded on Core, Select, ConnectorCare formularies |
| Wegovy (semaglutide 2.4 mg) | Not applicable (not a T2D-indicated product) | Excluded on most 2026 formularies; available on Value/Premium formularies with PA only |
| Zepbound (tirzepatide) | Not applicable (not a T2D-indicated product) | Excluded on most 2026 formularies; available on Value/Premium formularies with PA only |
| Saxenda (liraglutide 3 mg) | Not applicable (not a T2D-indicated product) | Excluded on most 2026 formularies |
Key policy dates:
- January 1, 2026: Weight-loss GLP-1 coverage terminated on Core, Select, ConnectorCare, and Tufts Health Direct formularies; all existing weight-loss PAs terminated — no grandfathering
- May 1, 2026: Automated step therapy removed for diabetic GLP-1 and GIP/GLP-1 medications; PA now required for all members on Premium, Select, Value, Core Massachusetts, Tufts Health Direct, and Value ConnectorCare formularies
- 2026 plan year: Value and Premium formulary members retain weight-loss GLP-1 coverage with PA, subject to formulary selection by employer group
Who this is for
- Harvard Pilgrim commercial members and their prescribers navigating GLP-1 prior authorization
- Benefit verification specialists and hub teams handling Harvard Pilgrim pharmacy claims
- Market access teams at GLP-1 manufacturers tracking Point32Health policy changes
- Employer benefits administrators evaluating Harvard Pilgrim GLP-1 coverage by formulary
- Tufts Health Direct members whose GLP-1 policies mirror Harvard Pilgrim commercial changes
Source standard
Every fact in this guide is sourced from Point32Health provider bulletins, Harvard Pilgrim formulary documents, Optum Rx prescription drug lists, and CMS publications dated 2025–2026. Harvard Pilgrim coverage rules vary by formulary, state, and employer group. Always verify current coverage by calling the member services number on your Harvard Pilgrim card or checking the Harvard Pilgrim member portal at harvardpilgrim.org.
Harvard Pilgrim program overview and GLP-1 relevance
Harvard Pilgrim Health Care is part of Point32Health, the parent organization formed from the merger of Harvard Pilgrim and Tufts Health Plan. Key structural features relevant to GLP-1 coverage:
- Pharmacy benefit manager: Optum Rx manages pharmacy benefits for Harvard Pilgrim commercial plans, including formulary management and specialty pharmacy routing
- Formulary structure: Harvard Pilgrim uses multiple formularies — Core (MA 3-tier, MA 5-tier, ME 5-tier, NH 4-tier, NH 5-tier, RI 5-tier), Premium (3-tier, 4-tier), Select (3-tier, 4-tier), and Value (4-tier, 5-tier, ConnectorCare 3-tier) — with different GLP-1 tier placements and coverage rules
- Geography: Plans operate in Massachusetts, Maine, New Hampshire, and Rhode Island; formulary options vary by state
- Weight-loss exclusion scope: The January 2026 exclusion covers all GLP-1 drugs "to treat weight loss and related conditions, such as cardiovascular disease" — a broader exclusion than many BCBS plans that continue covering MACE-prevention Wegovy
January 2026 weight-loss GLP-1 exclusion
What changed
Effective January 1, 2026, Harvard Pilgrim excluded coverage of all weight-loss drugs, including GLP-1 drugs, on most formularies. This exclusion applies to:
- Core formularies (all states): Core MA 3-Tier, Core MA 5-Tier, Core ME 5-Tier, Core NH 4-Tier, Core NH 5-Tier, Core RI 5-Tier
- Select formularies: Select 3-Tier, Select 4-Tier
- Tufts Health Direct formulary
- Value ConnectorCare 3-Tier
What was not excluded
GLP-1 medications prescribed for the treatment of type 2 diabetes remain covered with prior authorization on all formularies. This includes Ozempic, Mounjaro, Rybelsus, Trulicity, and other incretin therapies when prescribed for a documented T2D diagnosis.
Formularies that still cover weight-loss GLP-1s
Members on the following formularies retain weight-loss GLP-1 coverage, subject to prior authorization:
- Premium formularies (3-Tier, 4-Tier): Weight-loss GLP-1 coverage remains available with PA
- Value formularies (4-Tier, 5-Tier): Weight-loss GLP-1 coverage remains available with PA
Whether a member has access to a Premium or Value formulary depends on their employer group's 2026 plan selection. Formulary choice is made at the employer-group level, not by the individual member.
Prior authorization termination
Members previously approved for a weight-loss GLP-1 medication had their authorization terminated on January 1, 2026, or upon group anniversary. Point32Health confirmed there will be no grandfathering of prior authorizations. Members who need to continue therapy must either:
- Have their prescriber submit a new PA if their formulary still covers weight-loss GLP-1s (Value/Premium), or
- Pay out of pocket, or
- Explore alternative covered treatments through their prescriber
May 2026 diabetic GLP-1 PA changes
Step therapy removal
Effective May 1, 2026, Point32Health removed the automated step therapy program for diabetic GLP-1 and GIP/GLP-1 medications on the following formularies:
- Premium, Select, Value, Core Massachusetts
- Tufts Health Direct
- Value ConnectorCare
New PA criteria for diabetic GLP-1s
Prior authorization is now required for all members on these formularies for diabetic GLP-1 and GIP/GLP-1 medications, including Bydureon BCise, Byetta, Mounjaro, Ozempic, Rybelsus, and Trulicity. The PA criteria specify:
- Diagnosis requirement: Coverage is only available if the member has a diagnosis of type 2 diabetes
- Oral hypoglycemic trial: The member must have a trial and failure of a 30-day supply — or be currently taking — an oral hypoglycemic agent
- Off-label prevention: The criteria are intended to reduce or prevent off-label use for weight loss
What this means for prescribers
Prescribers must submit PA requests through the standard medical review process, subject to Point32Health's Pharmacy Medical Necessity Guidelines for Incretin Mimetics. The key documentation requirements:
- Documented T2D diagnosis (ICD-10 code required)
- Evidence of current or prior trial of oral hypoglycemic agent (metformin, sulfonylurea, etc.)
- Clinical rationale for the specific GLP-1 agent requested
Formulary-level GLP-1 coverage summary
| Formulary | T2D GLP-1 Coverage | Weight-Loss GLP-1 Coverage | PA Required |
|---|---|---|---|
| Core MA 3-Tier | Covered | Excluded | PA for T2D |
| Core MA 5-Tier | Covered | Excluded | PA for T2D |
| Core ME 5-Tier | Covered | Excluded | PA for T2D |
| Core NH 4-Tier | Covered | Excluded | PA for T2D |
| Core NH 5-Tier | Covered | Excluded | PA for T2D |
| Core RI 5-Tier | Covered | Excluded | PA for T2D |
| Select 3-Tier | Covered | Excluded | PA for T2D |
| Select 4-Tier | Covered | Excluded | PA for T2D |
| Premium 3-Tier | Covered | Covered with PA | PA for both |
| Premium 4-Tier | Covered | Covered with PA | PA for both |
| Value 4-Tier | Covered | Covered with PA | PA for both |
| Value 5-Tier | Covered | Covered with PA | PA for both |
| Value ConnectorCare 3-Tier | Covered | Excluded | PA for T2D |
How to determine your formulary
Because Harvard Pilgrim's GLP-1 coverage depends entirely on which formulary your employer group selected for 2026, the first step in any coverage investigation is formulary identification:
- Check your member ID card: The formulary name may be printed on the card
- Log in to the Harvard Pilgrim member portal at harvardpilgrim.org: Select "Prescription Drug Plans" and identify your formulary from the list
- Call Member Services: Contact the number on your ID card and ask which formulary applies to your plan
- Ask your employer's HR department: For employer-sponsored plans, HR can confirm the formulary selection
Prior authorization workflow for diabetic GLP-1s
Step 1: Confirm T2D diagnosis and oral agent trial
Before submitting PA, confirm:
- The member has a documented type 2 diabetes diagnosis
- The member has trialed or is currently taking an oral hypoglycemic agent for at least 30 days
Step 2: Gather documentation
Collect:
- T2D diagnosis with ICD-10 code (E11.x series)
- Documentation of oral hypoglycemic trial (prescription records, pharmacy fill history, or prescriber attestation)
- Current BMI and weight documentation
- Relevant lab results (HbA1c, fasting glucose)
- Medical necessity rationale for the specific GLP-1 agent
Step 3: Submit PA through Optum Rx
Prescribers submit PA through:
- Optum Rx provider portal
- Phone: Contact the Optum Rx number on the member's ID card
- Fax: Use the standard PA fax form available through the Point32Health provider portal
Step 4: PA decision timeline
Point32Health aims to process standard PA requests within 72 hours or two business days, whichever is less, for formulary exception requests. For urgent cases, the expedited review timeline is 24 hours.
Step 5: Appeal if denied
If PA is denied:
- Request the specific denial reason and reference number in writing
- Gather additional supporting clinical documentation
- Submit a first-level appeal to Point32Health
- If the first-level appeal is denied, request a second-level appeal or external review
Exception and appeal process
Formulary exceptions
For members who need a non-formulary GLP-1 or a GLP-1 that is excluded on their formulary:
- Members: Complete the exception request form available at harvardpilgrim.org and submit it to Harvard Pilgrim
- Providers: Complete the formulary exception request form and fax it to 617-673-0988, or call Provider Services at 800-708-4414
- Decision timeline: 72 hours or two business days (whichever is less); 24 hours for expedited requests when delay would jeopardize life or health
Appeals
Harvard Pilgrim's appeal process allows:
- Internal appeal within the plan's specified timeframe
- External review for clinical disputes
- Expedited external review at the same time as the internal appeal
Weight-loss alternatives still covered
Harvard Pilgrim continues to offer the following weight-management resources for members who lose GLP-1 coverage:
- Fitness reimbursement: Up to $300 per policy per calendar year for fitness club membership (requires active enrollment for at least four months within the calendar year)
- Bariatric surgery: Covered for members with health risks from obesity (subject to medical necessity criteria)
- Wellness programs: Access to nutrition support, weight-management counseling, and digital wellness tools
- Behavioral health support: Coverage for counseling and behavioral modification programs
What to monitor
- Value/Premium formulary changes: Employer groups renewing throughout 2026 may change formulary selection, which could add or remove weight-loss GLP-1 coverage. Monitor plan renewal communications
- CMS Medicare GLP-1 expansion: The July 2026 Medicare GLP-1 Bridge demonstration and BALANCE model launching in 2027 could affect Harvard Pilgrim Medicare Advantage plans
- New GLP-1 approvals: Orforglipron (Foundayo), FDA-approved in April 2026, and other oral GLP-1s may shift Optum Rx formulary strategy and step therapy hierarchies for Harvard Pilgrim
- State legislative action: Massachusetts, Maine, and other New England states are considering GLP-1 coverage mandates that could override Harvard Pilgrim's exclusion for state-regulated plans
- CVS Caremark formulary updates: CVS Caremark's May 2026 announcement reintroducing Zepbound to commercial formularies and removing the new-to-market block on Foundayo may affect Caremark-managed Harvard Pilgrim self-funded plans
Sources
- Point32Health. "Update on coverage of weight loss medication." September 2025. https://www.point32health.org/provider/update-coverage-weight-loss-medication-092025
- Point32Health. "Update on diabetic GLP-1 and GIP/GLP-1 drug coverage." January 2026. https://www.point32health.org/provider/update-diabetic-glp-1-and-gipglp-1-drug-coverage-012026
- Harvard Pilgrim Health Care. "Important drug coverage updates for Harvard Pilgrim Health Care members." September 2025. https://www.harvardpilgrim.org/public/news/important-drug-coverage-updates-harvard-pilgrim-health-care-members
- Harvard Pilgrim Health Care. "What You Need to Know for 2026 — Massachusetts Small Group." 2026 Plan Year. https://www.harvardpilgrim.org/documents/broker/2026-what-you-need-know-ma-sg
- Harvard Pilgrim Health Care. "Request an exception." https://www.harvardpilgrim.org/public/request-an-exception
- Optum Rx. "2026 Prescription Drug List — Harvard Pilgrim Health Care Core NH 5-Tier Comprehensive Formulary." September 2025. https://contenthub-aem.optumrx.com/content/dam/contenthub/rx-assets/en/documents/clients/harvard-pilgrim/p32-formulary-documents/2026-P32H-Core-NH-5T-Comprehensive-HPHC-Formulary-Booklet.pdf
- Harvard Pilgrim Health Care. "Prescription drug plans." https://www.harvardpilgrim.org/public/prescription-drug-plans
- Harvard University Human Resources. "GLP-1 2026 Clinical Changes and Coverage Requirements FAQs." October 2025. https://harvie.harvard.edu/sites/g/files/omnuum12046/files/2025-10/GLP1_Clinical_Changes_FAQ.pdf
- Word & Brown General Agency. "Weight Loss Drugs (GLP-1) Insurance Coverage Breakdown By Carrier." Updated May 1, 2026. https://www.wordandbrown.com/NewsPost/Weight-Loss-Drugs-(GLP-1)-Coverage
- CMS.gov. "Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries." 2026. https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries
